Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare Progression Free Survival (PFS) per RECIST 1.1 by central imaging vendor in subjects with first line (1L) stage IV MSI-H or dMMR CRC treated with pembrolizumab versus SOC chemotherapies.
Critère d'inclusion
- Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma